ANL Stock Forecast & Price Target

Adlai Nortye is viewed positively because it has moved from a preclinical story to a materially de-risked clinical-stage RAS franchise, with AN9025 now in Phase 1 and AN4035 already dosed in Australia and cleared by the FDA, creating a clear catalyst path into 1H27 and 2H27. The fundamental investment case is driven by differentiated biology and delivery: AN9025 offers a potentially best-in-class oral pan-RAS(ON) profile with strong preclinical potency and a projected human QD therapeutic index of 6.9x versus 5.2x for daraxonrasib, while AN4035 is a first-in-human CEACAM5-targeted ADC that aims to localize pan-RAS inhibition in tumors and address the off-tumor toxicity that has limited systemic pan-RAS dosing. Financially, the company remains pre-revenue and is still dependent on successful clinical execution, but its modest market cap of about $730M, recent financing that management says extends runway into 2029-30, and exposure to large RAS-driven markets such as 1L mPDAC support the view that positive data could trigger a significant re-rating.

Adlai Nortye is a high-risk, pre-profitability clinical-stage biotech whose value depends heavily on unproven assets, with AN9025 carrying only a 20% probability of success and AN4035 15%, while the company’s operating expenses are expected to rise as trials advance and could further strain liquidity if funding is not secured. Its lead RAS program, AN9025, faces meaningful competitive and execution risk because its clinical and commercial profile may be less compelling than rival pan-RAS approaches, and the thesis explicitly depends on a favorable Ph1 readout in 1H27 to de-risk the asset, narrow the valuation gap, and support broader combination potential. Although the ASK Pharma deal provides validation and could deliver up to about $230 million in milestones plus high-single-digit to mid-teens royalties, the company still remains dependent on future clinical data, potential partnerships, and non-dilutive financing, leaving the stock exposed to failed or inconclusive trials and dilutive capital raises.